Search Results

You are looking at 91 - 100 of 775 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman

2005 ; 23 : 569 – 575 . 16. Lyman GH Lyman CH Agboola O . Risk models for predicting chemotherapy-induced neutropenia . Oncologist 2005 ; 10 : 427 – 437 . 17. Gomez H Hidalgo M Casanova L . Risk factors for treatment

Full access

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente, and Francisco Ayala de la Peña

have DM. 14 , 15 Because DM is itself a cause of peripheral neuropathy, PIPN might be more prevalent and severe in patients with breast cancer and DM. However, the available evidence is limited for considering DM a risk factor for PIPN. Several case

Full access

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

Identify psychological risk factors for PPBCT that may be targeted in preventive interventions Background Persistent pain after breast cancer treatment (PPBCT) affects 25% to 60% of patients treated for breast cancer, 1 may persist for

Full access

Monira Alwhaibi, Usha Sambamoorthi, Suresh Madhavan, Thomas Bias, Kimberly Kelly, and James Walkup

). These dimensions are an individual's physical make-up, social support, access to care, health behaviors, psychological factors, biological risk factors, treatment factors, community resources, and geographic region. Methods Data Source SEER

Full access

Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna

, prevention strategies, and newer treatment modalities for CDI. 4 – 9 Patients with cancer are particularly vulnerable to CDI, which is attributed to traditional risk factors such as age; cancer itself; hospitalization and health care exposure; chemotherapy

Full access

Cocav A. Engman and Leo R. Zacharski

responsible for the content and editorial decisions regarding this manuscript. References 1. Heit JA Silverstein MD Mohr DN . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study . Arch Intern

Full access

Francis P. Worden and Huan Ha

risk factor for the increase in incidence of tonsillar cancer . Int J Cancer 2006 ; 119 : 2620 – 2623 . 9. D'Souza G Kreimer AR Viscidi R . Case-control study of human papillomavirus and oropharyngeal cancer . N Engl J Med 2007 ; 356

Full access

Scott Cooper, Mohammed Zaher, and Gregory Diorio

.S. Surveillance, Epidemiology, and End Results registry (SEER). Clinical identification of risk factors for adverse outcomes will allow for patient-specific counseling on prognosis and intervention. Methods: Population-based data from SEER 18 was used to assess

Full access

Himani Aggarwal, Li Li, Gebra Cuyun Carter, Kathy Fraeman, and Ariel Berger

risk factors included alcohol use, diabetes, and distant metastases. Conclusions: HPV-positive status was associated with a decreased risk of mortality among OPC patients in this study. Despite the small sample size and potential violation of

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang

. The panel has focused on outlining reasonable treatment options based on recent clinical trials and data from basic science, which may identify new risk factors and treatment approaches. In some areas, panel members have divergent opinions about the